Melodiol Global Health Limited (ASX: ME1) announced a trading halt on 4th June 2021, in response to a series of requests from the Australian Securities Exchange (ASX). The halt was initiated pending the release of an imminent announcement, confirming the company’s financial year 2021 result.
The company’s trading halt will remain in effect until the earlier of the announcement being released to the market, or the commencement of trading on Monday 7th June 2021.
Melodiol Global Health Is a clinically-accredited global provider of holistic health solutions and services using a range of therapeutic techniques. These include a holistic approach to physical, mental, and emotional health.
The company aims to provide safe, ethical, and scientifically sound clinical care to the community. Their philosophy is based on the integration of western/conventional medicine, Chinese Medicine theory, Oriental Complementary Medicine Practice and a range of lifestyle, psychological, mindfulness and lifestyle-based approaches designed to support mental, emotional and physical health.
Melodiol Global Health is committed to delivering high-quality, evidence-based healthcare solutions and supporting its clients to achieve their health goals.
To achieve this, Melodiol Global Health has invested significantly in its quality management system – continuously improving its processes and practices to ensure the safety and effectiveness of its treatments.
The Australian Securities Exchange has requested that Melodiol Global Health limited provide the information requested in order to meet the necessary listing requirements and ensure the health of its shareholders.
Melodiol Global Health’s halt in trading pending the release of the financial year 2021 result should be resolved soon and the expectation is that the release of this result will provide investors with additional information and insight into Melodiol Global Health, as well as further advance its compliance with the Exchange’s listing rules.
Melodiol Global Health Limited (ASX: ME1) announced a trading halt on 4th June 2021, in response to a series of requests from the Australian Securities Exchange (ASX). The halt was initiated pending the release of an imminent announcement, confirming the company’s financial year 2021 result.
The company’s trading halt will remain in effect until the earlier of the announcement being released to the market, or the commencement of trading on Monday 7th June 2021.
Melodiol Global Health Is a clinically-accredited global provider of holistic health solutions and services using a range of therapeutic techniques. These include a holistic approach to physical, mental, and emotional health.
The company aims to provide safe, ethical, and scientifically sound clinical care to the community. Their philosophy is based on the integration of western/conventional medicine, Chinese Medicine theory, Oriental Complementary Medicine Practice and a range of lifestyle, psychological, mindfulness and lifestyle-based approaches designed to support mental, emotional and physical health.
Melodiol Global Health is committed to delivering high-quality, evidence-based healthcare solutions and supporting its clients to achieve their health goals.
To achieve this, Melodiol Global Health has invested significantly in its quality management system – continuously improving its processes and practices to ensure the safety and effectiveness of its treatments.
The Australian Securities Exchange has requested that Melodiol Global Health limited provide the information requested in order to meet the necessary listing requirements and ensure the health of its shareholders.
Melodiol Global Health’s halt in trading pending the release of the financial year 2021 result should be resolved soon and the expectation is that the release of this result will provide investors with additional information and insight into Melodiol Global Health, as well as further advance its compliance with the Exchange’s listing rules.
